| 000 | 01889 a2200541 4500 | ||
|---|---|---|---|
| 005 | 20250517160255.0 | ||
| 264 | 0 | _c20181102 | |
| 008 | 201811s 0 0 eng d | ||
| 022 | _a1399-5448 | ||
| 024 | 7 |
_a10.1111/pedi.12545 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aIlonen, Jorma | |
| 245 | 0 | 0 |
_aPrimary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity. _h[electronic resource] |
| 260 |
_bPediatric diabetes _c03 2018 |
||
| 300 |
_a284-292 p. _bdigital |
||
| 500 | _aPublication Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 |
_aAutoantibodies _xanalysis |
| 650 | 0 | 4 | _aAutoimmunity |
| 650 | 0 | 4 |
_aBiomarkers _xblood |
| 650 | 0 | 4 | _aCohort Studies |
| 650 | 0 | 4 |
_aDiabetes Mellitus, Type 1 _xblood |
| 650 | 0 | 4 | _aFamily Health |
| 650 | 0 | 4 | _aFemale |
| 650 | 0 | 4 | _aFinland |
| 650 | 0 | 4 | _aFollow-Up Studies |
| 650 | 0 | 4 | _aGenetic Predisposition to Disease |
| 650 | 0 | 4 |
_aGlutamate Decarboxylase _xantagonists & inhibitors |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 |
_aIkaros Transcription Factor _xantagonists & inhibitors |
| 650 | 0 | 4 | _aInfant, Newborn |
| 650 | 0 | 4 |
_aInsulin _xchemistry |
| 650 | 0 | 4 | _aKaplan-Meier Estimate |
| 650 | 0 | 4 | _aMale |
| 650 | 0 | 4 | _aPolymorphism, Single Nucleotide |
| 650 | 0 | 4 |
_aReceptor, ErbB-3 _xantagonists & inhibitors |
| 650 | 0 | 4 | _aRegistries |
| 650 | 0 | 4 | _aSeroconversion |
| 650 | 0 | 4 |
_aZinc Transporter 8 _xantagonists & inhibitors |
| 700 | 1 | _aLempainen, Johanna | |
| 700 | 1 | _aHammais, Anna | |
| 700 | 1 | _aLaine, Antti-Pekka | |
| 700 | 1 | _aHärkönen, Taina | |
| 700 | 1 | _aToppari, Jorma | |
| 700 | 1 | _aVeijola, Riitta | |
| 700 | 1 | _aKnip, Mikael | |
| 773 | 0 |
_tPediatric diabetes _gvol. 19 _gno. 2 _gp. 284-292 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1111/pedi.12545 _zAvailable from publisher's website |
| 999 |
_c27261700 _d27261700 |
||